It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Purpose
An earlier multicenter phase III study demonstrated the safety and efficacy of mitoxantrone hydrochloride injection for tracing (MHI) for detecting sentinel lymph nodes (SLNs) in breast cancer patients. This ancillary study was conducted to further analyze and discover differences between the two tracers that had not been reported previously.
Methods
This analysis used single-center data from a phase III trial. Patients with breast cancer were injected with both MHI and 99mTc as SLN tracers before surgery. To account for cluster effects of multiple SLNs from the same patient and further analyze the differences between the two methods and factors that could impact detection, Obuchowski’s modified McNemar test, the GLIMMIX model, and univariate and multivariate analyses were used as appropriate.
Results
In total, 463 SLNs from 109 patients were resected, 47 of which were pathologically positive. The SLN detection rate did not significantly differ between MHI and 99mTc. MHI blue staining was an independent predictor of pathological positivity (OR 3.58, 95% CI: 1.21–10.60, p = 0.02), while the 99mTc signal was not significant in the same model (p = 0.39).
Conclusion
MHI was comparable to 99mTc in safety and SLN detection rates but differed in sensitivity on positive SLNs.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer